In this fourth episode of the 6-part series, an expert explains what COVID-19 treatments are available in the outpatient setting. The focus is on monoclonal antibodies—bamlanivimab + etesevimab and casirivimab + imdevimab. For both drug combinations, he discusses the Emergency Use Authorization (EUA) indications, efficacy evidence, and potential toxicities.
In Partnership With the Association of Pulmonary Advanced Practice Providers
After completing this activity, participants should be better able to:
- Formulate strategies for appropriate use of outpatient EUA-approved therapies for COVID-19
APPs in Pulmonology, Critical Care, Infectious Disease, and APP Hospitalists
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Corinne R. Young, MSN, FNP-C, FCCP, Association of Pulmonary Advanced Practice Providers, Colorado Springs, Colorado
Nursing contact hours: 0.25, which includes 0.25 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until April 29, 2022. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Mr Hardisty has no relevant financial relationships to disclose.
Dr Ison: contracted research: GlaxoSmithKline; consulting: Adagio, AlloVir, Celltrion, Cidara, Roche, Takeda, ViraCor Eurofin.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Listen to the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 100%.
The estimated time to complete this activity is 0.25 hours.
Release date: April 30, 2021
Expiration date: April 29, 2022
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 101821RG-4